Improving medication adherence: the role of the health care delivery
Analysis of factors associated with statin adherence in a hierarchical
Hypertension, prescription drug copayments and drug therapy
Measuring adherence to antihypertensive drug therapy. [letter]
Patient adherence with hypertension medication. [letter]

Adverse Drug Events
• Indicators of preventable drug-related morbidity in older adults. 2. Use within a managed care organization. 2003,9(2):134-41.
• Medical errors, adverse medical events, and PDRM. 2002,8(5):400.
• Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. 2001,7(5):402-06.

Behavioral Health
• Issues and trends in behavioral health and managed care. 2000,6(1):11-12, 15-16.

Biotechnology

Capitation and Risk-Financing Methods
• Contractual arrangements between HMOs and medical groups to manage drug costs. [editorial] 2003,9(6):372.
• Managing pharmacy risk in physician groups. 1999,5(5):382-84.

Clinical Pharmacy—Patient Consultation

**Clinical Pharmacy—Payment for Services—Medication Therapy Management**

• Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. 2009;15(1):18-31.
• PSTAC survey in 2006 was instrumental in obtaining permanent (category 1) CPT codes for MTM services performed by pharmacists. [letter] 2008;14(1):86-87.
• Mississippi Medicaid waiver breaks new ground for pharmacists. 1996;2(6):564, 566.

**Clinical Pharmacy Interventions—Quality, Service, and Cost Outcomes**

• A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. 2008;14(9):831-43.
• Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. 2007;13(1):28-36.
• Experience with a clinical decision support system in community pharmacies to recommend narrow-spectrum antimicrobials, nonantimicrobial prescriptions, and OTC products to decrease broad-spectrum antimicrobial use. 2006;12(5):390-97.

**Clinical Pharmacy Quality Improvement—Patient Safety and Prevention of ADEs**

• Sources and types of discrepancies between electronic medical records and actual outpatient medication use. 2008;14(7):626-31.
• Integration of medical and pharmacy claims to better protect patient safety—a long road yet to travel. 2007;13(5):429-30.
• Preventing medication errors and adverse drug events. 2003;9(1):92-93.
• Quality improvement, risk management, and patient education: tools to reduce medication error. 2001;7(2):156-63.

Clinical Practice Guidelines (CPGs), Evidence-Based Practice and Quality Improvement

• Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs. 2009;15(4):323-34.
• Call for letters regarding disclosure of potential conflicts of interest in the managed care literature – Too much, too little, or just about right? [editorial] 2009;15(2):166.
• Rethinking the “whodunnit” approach to assessing the quality of health care research – a call to focus on the evidence in evidence-based practice. [editorial] 2008;14(7):661-74.
• Looking for the outcomes we love in all the wrong places: the questionable value of biomarkers and investments in chronic care disease management interventions. 2008;14(6):563-70.
• Evaluation of the relationship between a chronic disease care management program and California pay-for-performance diabetes care cholesterol measures in one medical group. 2007;13(7):578-88.
• Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. 2006;12(8):656-64.
• Adherence to the NASPE guideline for amiodarone monitoring at a medical university. 2006;12(3):254-59.
• Evidence-based medicine: beware of results from randomized controlled trials and research with administrative claims data. [editorial] 2005;11(2):172.
• Framework for pharmacy services quality improvement—a bridge to cross the quality chasm. 2004;10(1):60-78.
• Consensus panel, national guidelines, and other potentially misleading terms. [editorial] 2003;9(6):575-76.

• Information technology to cross the quality chasm. 2002;8(5):401-02.
• Crossing the quality chasm—incremental change through clinical practice guidelines (CPGs). [editorial ] 2002;8(5):400-01.
• Quality improvement opportunities in health care—making it easy to do it right. 2002;8(5):394-99.
• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritic population in a large HMO. 2002;8(4):252-58.
• Quality measures: looking in all the wrong places. 2001;7(2):88.
• Medical and medication errors: a partial summary of reports by the Institute of Medicine and the quality interagency coordination task force. 2001;7(1):62-68.
• The case for pharmacy report cards. 1999;5(3):176, 179-80, 182.
• Managing drug therapy decisions: pay me now or pay me later. 1998;4(2):242, 245.
• How to evaluate disease state management programs. 1997;3(3):270, 273-74, 277-78.
• Managed care and the quest for quality measures. 1997;3(3):255, 258-89.
• Successful CQI-based programs in a group-model managed care setting. 1995;1(2):134, 137.

Collaboration—Pharmacists and Others

• Prevalence and types of disease management programs in community pharmacies in California. 2005;11(6):505-12.

Pharmacy practice in the long-term care environment. 1997;3(2):189-94.

Collaboration—Pharmacy Education


Oregon State University partners with Medicaid and a managed care organization. 2001;7(3):185-86.

The University of Colorado School of Pharmacy and the University of Colorado Health Plan forge a PBM partnership. 1998;4(5):478, 480.


Database Analyses of Drug Utilization (see also Research Methods)


Claims data and drawing appropriate conclusions. 2002;8(2):152.


Decision Support Systems (DSS)


Direct-to-Consumer Advertising (DTCA)

(see also Drug Promotion and Advertising)

United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market. [editorial] 2005;11(2):176-78.

Direct-to-patient advertising (DTPA) and direct-to-consumer advertising (DTCA) of prescription drugs. 2002;8(6):521.


Responding to direct-to-consumer advertising. 2000;6(3):201-02.


Disease Management—Airway Disease and Allergic Rhinitis


Quality of drug treatment of childhood persistent asthma in Maryland Medicaid recipients in transition from managed fee to managed capitation. 2007,13(4):310-18.


Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol. [letter] 2006;12(6):486-87.


More evolution of the evidence in asthma disease management—SMART versus GOAL clinical trials debate the cost-benefit of LABA while the value of leukotriene modifiers, particularly montelukast, is uncertain. [editorial] 2006;12(4):343-46.


Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. 2006;12(4):310-21.


Selectivity and specificity are the cost-effective use of omalizumab for allergic asthma. [editorial] 2005,11(9):774-76.


• Optimizing clinical and economic outcomes in asthma management: individualizing drug therapy to address dual components of asthma. [supplement] 2002;8(5):S1-S25.


• Evaluating asthma medication use before and after an acute asthma-related event. 2001;7(4):303-08.


**Disease Management—ALS (Amyotrophic Lateral Sclerosis)**


**Disease Management—Alzheimer’s Disease**

• Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts. [commentary] 2008;14(5):462-64.


**Disease Management—ACS, Atrial Fibrillation, CHD, and CHF**


• Association between the use of 4 recommended drug categories and patients perceptions of health status following an ACS event. 2009;15(7):533-42.


• Total first-year costs of acute coronary syndrome in a managed care setting. 2005;11(4):300-06.


**Disease Management—Arthritis and Joint Pain**


• Modernization versus limitation: cross-firing the impact of the AIRIQ Effective Care Health Care Program on access to biologic therapies. [supplement] 2007;13(1):S1-S24.

• Review of eight pharmaceoeconomic studies of the value of biologic (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. 2006;12(7):555-69.


• COX-2 inhibitors: little or no GI protection, increased risk of cardiovascular events, high cost, and other class-less effects. [editorial] 2005;11(7):590-93.

• Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. 2005;11(7):550-58.


• Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. 2002;8(4):252-58.

• Economic considerations in the management of arthritis. 1999;5(6):476-78, 481-82, 484.


**Disease Management—Atopic Dermatitis**

• Atopic march to a dead end or does the theory really have legs? [editorial] 2007;13(9):810-11.


• Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. 2007;13(4):349-59.


• Changes and challenges: managing ADHD in a fast-pace world. [supplement] 2007;13(9), S-1-S;S1-S16.

• ADD or ADHD or what exactly? – GIGO part II and other lessons in research with administrative claims. [editorial] 2007;13(7):617-19.
• Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. 2007;13(7):570-77.

• Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. 2007;13(7):561-69.


• Physician perceptions of the use of medications for attention deficit hyperactivity disorder. 2003;9(5):416-23.

Disease Management—Benign Prostatic Hyperplasia


Disease Management—Cancer


• Budget impact analysis of ixabepilone use according to FDA-approved labeling in treatment-resistant metastatic breast cancer. 2009;15(6):467-75.

• Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. 2008;14(9):858-69.


• Recent advances in the understanding and treatment of multiple myeloma. [supplement] 2008;14(7-8):S1-S29.


• Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. 2007;13(4):337-48.

• Pharmacy benefit spending on oral chemotherapy drugs. 2006;12(7):570-77.


Disease Management—Diabetes

(see also Clinical Pharmacy Interventions—Quality, Service, and Cost Outcomes)


Economic impact of antidiabetic medications and glycemic control on managed care organizations: a private payer’s experience. 2006;12(9):726-35.


Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. 2006;12(7):548-54.

What are incretins, and how will they influence the management of type 2 diabetes? [supplement] 2006;12(7, S-a):S1-S16.

Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. 2006;12(6):466-71.

Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. 2006;12(4):303-09.


Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population. 2006;12(2):121-29.


Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. 2005;11(7):559-64.


Evaluating medication use for continuous quality improvement in diabetes care. 2002;8(9):378-82.


Disease Management—Dyslipidemia


LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. 2007;13(8):652-63.

Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. 2006;12(9):745-51.


Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA medical centers. 2005;11(9):763-71.

Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. 2005;11(8):681-86.

Fish oil for heart disease—happy to be in second place. [editorial] 2005;11(7):584-85.

Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. 2005;11(6):499-504.


Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. 2004;10(3):244-50.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Relevant Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease Management</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Gout</strong></td>
<td>Disease-related and all-cause health care costs of elderly patients with gout. 2008;14(2):164-75.</td>
</tr>
<tr>
<td><strong>Heartburn and Acid-Related Disorders</strong></td>
<td>Employers need to have a wider horizon than drug costs alone when considering the implementation of health care intervention programs. (letter and author response) 2006;12(7):581-83.</td>
</tr>
<tr>
<td><strong>Hypertension and Cardiovascular Disease</strong></td>
<td>Applying quality measures and guidelines in the management of acute coronary syndrome and venous thromboembolism. [supplement] 2008;14(6, S-a):S1-S29.</td>
</tr>
<tr>
<td><strong>Infectious Disease</strong></td>
<td>Initiation of statins after hospitalization for coronary heart disease. 2007;13(5):385-96.</td>
</tr>
</tbody>
</table>

**JMCP Article Index by Subject Category — With Hyperlinks**

www.amcp.org Vol. 15, No. 9 November/December 2009 JMCP Journal of Managed Care Pharmacy 783
• Fluroquinolone-use evaluation by acute cystitis. 1996;2(5):564-68.

Disease Management—Irritable Bowel Syndrome
• Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. 2008;14(9):870-77.

Disease Management—Kidney Disease
• Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. 2006;12(9):714-25.

Disease Management—Migraine Syndrome
• There is value in anecdotal reports of relief from migraine with botulinum toxin. [letter and author response] 2009;15(1):78-79.
• Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatRIPTAN ODT in primary care patients with migraine headaches. 2006;12(3):246-53.
• Which is more elusive, the pot of gold at the end of a rainbow or determining the most cost-effective triptan? [editorial] 2005;11(6):S13-15.
• Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. 2005;11(5):394-402.
• Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. 2003;11(2):137-44.
• Prevalence and burden of illness of migraine in managed care patients. 2003;11(2):124-36.
• Which triptan?—Opportunity for same or better outcomes at lower cost. [editorial] 2004;10(3):266.
• Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.

Disease Management—Multiple Sclerosis
• Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. 2007;13(1):44-52.

Disease Management—Obesity
• The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system. [supplement] 2006;12(1):S1-S16.
• “U Can’t Touch This” with pharmacotherapy alone for weight loss or smoking cessation. [editorial] 2005;11(6):516-20.
• Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. 2005;11(6):458-68.
• A cost-effective analysis of appetite suppressants for obesity treatment in a managed care organization. 1998;4(3):293-300.

Disease Management—Osteoporosis
• 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. 2008;14(3):281-90.
• Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. 2004;10(2):142-51.


• ERT, HRT, raloxifene, calcitonin, or bisphosphonates for osteoporosis. 2003;9(2):178-181.

• The cost of treating osteoporosis in a managed care health organization. 2003;9(2):142-49.


Disease Management—Psoriasis


Disease Management—Parkinson’s


• Step therapy is not appropriate for antiepileptic drugs. [letter] 2006;12(3):269-70.


Disease Management—Thrombosis, DVT, and VTE

• Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. 2007;13(6):475-86.


• Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. 2005;11(9):755-62.

• In search of safe and effective oral anticoagulation. [editorial] 2005;11(8):704-08.

• Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. 2005;11(8):663-73.


Disease Management—Ulcerative Colitis


• The challenge of compliance and persistence: focus on ulcerative colitis. [supplement] 2008;14(1, S-a):S1-S16.

• Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. [supplement] 2007;13(7, S-a):S1-S16.

Disease Pathology and Prevention


Dose Optimization—Dose Consolidation and Tablet Splitting


• Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. 2006;12(6):449-56.

• Dose consolidation can be an efficient intervention. And author Response. (letters) 2004;10(6):564-66.

• Randomized controlled trial of a dose consolidation program. 2004;10(5):396-403.

• Dose-optimization intervention yields significant drug cost savings. 2002;8(2):146-51.

• Dose optimization: an opportunity for pharmacy administrative services. 2002;8(2):81.

Drug Benefit Management—Benchmarks and Measures

• Principles and practical applications of benchmarking. [supplement] 2005;11(1, S-a):S1-S23.

• Other DACON observations—community pharmacists do not intentionally transmit incorrect claim information—but caution is warranted in days supply calculations. [letter] 2004;10(2):174-75.

• Need for greater scrutiny of days supply values in DACON calculations. [letter] 2004;10(2):172-73.


• Searching for drug benefit benchmarks—cost per day of therapy. 2002;8(1):54-55.


Drug Benefit Management—Benefit Design


• The editors respond regarding the shortcomings in reported research on value-based insurance design. [letter] 2008;14(3):326-28.


• Making the world safe for evidence-based policy: let’s slay the biases in research on value-based insurance design. [editorial] 2008;14(2):198-204.

www.amcp.org Vol. 15, No 9 November/December 2009 JMCPO Journal of Managed Care Pharmacy 785

• Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. 2007;13(9):765-77.

• Factors associated with choice of pharmacy setting among DoD health care beneficiaries aged 65 years or older. 2007;13(8):677-86.

• The elephant in the pharmacy: patient choice is the big challenge that no one talks about in affordability of prescription drugs. [editorial] 2007;13(7):620-22.

• Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans. 2007;13(2):122-34.

• Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share. 2006;12(8):665-76.


• Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. 2006;12(5):377-82.


• The estimated impact of drug importation, mandatory mail service, and Medicaid fee reduction on community pharmacies in Michigan. 2006;12(2):157-63.

• A 30-month evaluation of the effects on cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. 2006;12(1):25-32.

• The role of pharmaceuticals in reducing cardiometabolic risk: rethinking pharmacy benefit design to reduce the burden on the health care system. [supplement] 2006;12(1):S1-S16.


• Effects of the cost and utilization of proton pump inhibitors from adding over-the-counter omeprazole to drug benefit coverage in a state employee health plan. 2004;10(5):449-55.

• Does member cost-sharing pose a threat to desirable patient outcomes? 2004;10(3):256.


• 3-tier drug benefit designs based on sound drug formulary principles will maximize favorable outcomes. [editorial] 2004;10(1):83-84.

• Benefit maximums versus drug benefit needs for Medicare beneficiaries. 2002;8(5):402-03.

• Prescription use behavior among Medicare beneficiaries with capped prescription benefits. 2002;8(5):360-64.


• Weight uniformity of split tablets required by a Veterans Affairs policy. 2003;9(5):401-07.

• Mail-order prescriptions requiring clarification contact with the prescriber: prevalence, reasons, and implications. 2003;9(4):346-52.

• Tablet splitting to improve the value-for-money equation in cholesterol management. 2002;8(6):519.


• A model to estimate drug plan cost savings from a trial prescription program. 2001;7(5):393-401.


• Pharmacy benefit administration options. 1996;2(3):272-78.

Drug Benefit Management—Employee Benefits and Coverage
(see also Drug Benefit Management—Benefit Design)

• Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan. 2007;13(2):135-41.


• Older adults’ drug benefit beliefs: a focus group study. 2005;11(1):77-85.


• Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. [supplement] 2004;10(3, S-a):S1-S20.


• New generic and OTC drugs provide opportunities for drug benefit managers. 2002;8(6):520.
Drug Benefit Management—Patient Satisfaction, Benefit Knowledge, and Consumer Behavior

- Drugs, PPOs, tiered cost-share for beneficiaries, and consumer preferences. 2002;8(3):177.
- Patient satisfaction with and knowledge of their prescription drug coverage. 2001;7(1):34-42.

Drug Benefit Management—Pharmacy Providers


Drug Benefit Management Methods - Quantity Limits, Step Therapy, Prior Authorization (PA), Drug Pricing and Rebates

- Perceptions of Saskatchewan community pharmacists regarding a prior-authorization program. 2007;13(7):580-97.
- Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. 2007;13(3):235-44.
- Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. 2005;11(8):674-80.
- Evaluation of a monthly coverage maximum (drug specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. 2003;9(4):335-45.
- Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. 2003;9(1):36-44.
- Medical and pharmacy cost and utilization outcomes of a quantity limit on 5-HT1 agonists (triptans) by a managed care organization. 2001;7(6):468-75.
Drug Promotion and Advertising
(see also Direct-to-Consumer Advertising [DTCA])
- Information requirements of health systems as drug purchasers: does the FDA have a role in setting evidentiary standards? 1998;4(6):593-98.

Drug Spending, Utilization, and Cost Trends
- Too much or too little? The role of pharmaceuticals in the health care system. 1999;5(4):296-97, 301-02.
- Local area market dynamics. 1998;4(2):115-17, 120.

Drug Therapy—Natural Products

Drug Therapy, Therapeutic Selection, and P&T Decision Making
- Here is the case for the urge in administrative claims database research about overactive bladder therapies. [commentary] 2008;14(3):309-11.
- Pharmacist intervention in safe and effective conversion of brand to generic drugs. [letter] 2005;11(9):777.
- Comparison of costs and utilization between users of insulin lispro versus users of regular insulin in a managed care setting. 2005;11(5):376-82.
- Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. 2003;9(3):263-68.
Drug Utilization Review (DUR) or Drug Utilization Management—Appropriate Drug Use

- Examination of multiple medication use among TRICARE beneficiaries aged 65 years and older. 2007;13(2):155-62.

- Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector Medicare HMOs. 2006;12(5):362-70.
- Gabapentin may be appropriate for off-label uses. [editorial] 2003;9(6):569-70.
- Examination of the evidence for off-label use of gabapentin. 2003;9(6):559-68.
- High frequency of itraconazole prescriptions with potentially interacting medications in a large health care plan. 2002;8(3):199-203.


Ethics


Formulary Management—Methods and Effects—Pharmacoeconomics

- Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary. 2009;13(1):42-34.
- Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. 2007;13(4):360-71.
• P&T committees—black boxes versus AMCP Format, and what is the true cost and value of pimecrolimus. [editorial] 2005;11(1):93-94.
• The role of pharmacy benefit managers in formulary design: service providers or fiduciaries? [letter] 2004;10(4):599-600.
• Formulary management methods and pharmacoeconomics. 2003;9(9):452-53.
• Industry's perception of presenting pharmacoeconomic models to managed care organizations. 2003;9(2):159-67.
• Summary quality scores for pharmacoeconomic studies: balancing validity with need. 2003;9(1):87-88.
• Examining the value and quality of health economic analyses: implications of utilizing the QHES. 2003;9(1):53-61.
• Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. 2003;9(1):45-52.
• Exploring the methodological challenges of investigating comparison groups with different underlying characteristics: a case study. 2002;8(5):393-59.
• AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. 2001;7(4):272-82.
• The pros and cons of formularies. 2000;6(3):203-07.
• The role of pharmacoeconomic information in the formulary decision-making process. 2000;6(2):108, 113-14, 117-18, 121.
• The impact of a therapeutic interchange program in a managed care organization. 1999;5(3):438-41.
• Outcome analysis of a formulary transition from nifedipine to felodipine at a Veterans Affairs Medical Center. 1999;5(3):425-28.
• Formulary management by an on-site school of pharmacy faculty member in a Medicaid managed care organization. 1998;4(4):407-10.
• DOD's Pharmacoeconomic Center: translating research into good patient care practices. 1997;3(6):662-64, 666.
• Drug formularies: real opportunities to improve MCO efficiency. 1997;3(3):254, 375-76.
• Using outcomes as a tool to evaluate formulary selection decisions: hypercholesterolemia as a case example. 1996;2(4):396-404.

Formulary Management—P&T Committees

Health Care Delivery and Health Promotion
• Shape It Up — A school-based education program to promote healthy eating and exercise developed by a health plan in collaboration with a college of pharmacy. 2009;15(5):403-13.
• A review of the use of CAM therapy and the sources of accurate and reliable information. 2005;11(8):695-703.
• Development of a complementary and alternative medicine (CAM) pharmacy and therapeutics (P&T) subcommittee and CAM guide for providers. 2005;11(3):232-38.
• International markets offer new opportunities for MCOs and PBMs. 1997;3(4):403-04, 409-10.
• Integration takes managed care in different directions: horizontal, vertical, and beyond. 1997;3(3):260, 263-64.
• Alternative medicine in managed care pharmacy. 1997;3(1):77-80, 83-86.
• Indian Health Service: paving the way for pharmaceutical care. 1997;3(1):36, 41-43.

Health Care Spending and Health Economics
• Fractal mathematics in managed care? How a simple and revealing tool can improve accountability for outcomes. 2007;13(9):799-806.
• Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. 2007;13(9):790-98.
• Is there no prescription to decrease health care outlays in the face of an aging population? 2000;6(6):450-51.
• Health economics II: some unique aspects of health economics. 2000;6(2):173-78.

Health Insurance and Health Care Finance
• Concern about foreign-source pharmacy Internet providers. 2001;7(5):335-36.
• The Internet and PBMs: new business model or business as usual? 2000;6(2):102, 105-07.

Lifestyle Drugs

Managed Care Pharmacy Practice
• Quality articles require peer reviewers—as well as authors. [letter] 2005;11(2):186.
• John Ogden talks about managed care in the Veterans Administration. 2002;8(2):91-93.
• Managed care and the pharmacy profession revisited. 1999;5(2):78.

• The changing face of managed care pharmacy and the role of PBMs. 1997,3(5):494, 497-98.
• Blue Cross and Blue Shield: making pharmaceutical care a key component of managed care. 1996,2(1):33-34, 36, 38.
• Professional opportunities in managed care pharmacy. 1995;1(2):80, 82, 86-87.
• Sound medication therapy management programs, version 2.0 – with validation study. [supplement] 2008;14(1-S-S):S1-S44.
• Unprecedented opportunities for managed care and community pharmacy to work together. 2007;13(3):426-28.
• Medication therapy management programs: when will the outcomes come out? [commentary] 2007;13(3):276-77.
• Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. 2007;13(2):142-54.
• Timeline and potential impact of CMS’s drug Competitive Acquisition Program (CAP). 2006;12(3):263-64.
• Medication Therapy Management Services for long-term care patients: no road maps for those trying to find their way. [editorial] 2005;11(7):856-87.
• Medication therapy management programs—will patient need be satisfied? [editorial] 2005;11(9):392-93.

Pain Management

• Beyond narcotics for effective pain management. 2003; 9(2):175-76.
• It’s a pain. 1999;5(6):558.

Pharmaceutical Industry and Marketing

• Pharmaceutical patient assistance programs don’t look a gift horse in the mouth or there’s no such thing as a free lunch. [commentary] 2007;13(7):614-16.
• Costs to physician offices of providing medications to medically indigent patients via pharmaceutical manufacturer prescription assistance programs. 2007;13(6):506-14.
• Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. 2005;11(9):746-54.

Pharmacogenomics

• Implications of pharmacogenomics in the current and future treatment of asthma. 2007;13(6):497-505.
• Drug therapy customized to individual patients. 2002;8(4):296-97.
• Health care professionals’ perceptions of the role of pharmacogenomic data. 2002;8(4):278-84.

Pharmacy Education

• Managed care and the University of Texas College of Pharmacy. 2001;7(6):490.
• University of Michigan College of Pharmacy and managed care partner to enhance drug therapy. 2001;7(5):345-46.
An inside look at the benefits of a student pharmacy and therapeutics (P&T) committee competition from the University of Illinois at Chicago. 2001;7(4):259-60.

Managed care concepts prominently featured in innovative management programs at Duquesne University. 2001;7(2):94-96.


The University of Maryland's Center on Drugs and Public Policy. 2000;6(2):184-85.


Managed care pharmacy practice at the Texas Tech University Health Sciences Center School of Pharmacy. 1999;5(6):556-57.

Description of a formal affiliation between a school of pharmacy and a managed care organization. 1999;5(5):433-37.


Improving efficiency and effectiveness in managed care: ongoing efforts at the University of New Mexico College of Pharmacy. 1999;5(2):111.


First managed care pharmacy course at the University of Illinois at Chicago. 1998;4(1):80-81.


Pharmacy internship offers real-world exposure to managed care pharmacy practice. 1997;3(4):605-06.

Managed care pharmacy at the St. Louis College of Pharmacy. 1996;2(4):439, 442.


Managed care pharmacy education at MCP. 1996;2(1):53.


UIC students mobilize first student chapter of AMCP. 1995;1(3):185-86.

Suboptimal pneumococcal pneumonia vaccination rates among patients at risk in a managed care organization in Israel. 2006;12(3):152-56.


The Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the pharmacy benefit: implications for health plans, PBMs, and providers. 2003;9(1):66-71.


Cruelty to numbers – just right or too much of a good thing? 2001;7(3):201-04, 213.

Peeking inside the statistical black box: how to analyze quantitative information and get it right the first time. [editorial] 2007;13(1):70-74.


Differentiating effective data mining from fishing, trapping, and cruelty to numbers – just right or too much of a good thing? [editorial] 2007;13(6):517-27.


Differentiating effective data mining from fishing, trapping, and cruelty to numbers – just right or too much of a good thing? [editorial] 2007;13(6):517-27.


Differentiating effective data mining from fishing, trapping, and cruelty to numbers – just right or too much of a good thing? [editorial] 2007;13(6):517-27.
### JMCP Article Index by Subject Category — With Hyperlinks

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
</table>
| Safety — Patient Care (see Drug Utilization Review [DUR]) | **Specialty Pharmacy**  
- Specialty pharmacy cost management strategies of private health care payers. 2006;12(9):736-44.  
- The emergence of specialty pharmacy. 2000;6(4):280-84. |
| Survey Methods (see also Research Methods) | Constructing mail survey questionnaires to maximize the rates of return and assure the validity and reliability of responses. 2002;8(3):225-31.  
- Use of technology throughout the curriculum. 2002;8(2):86.  
| Technology — Electronic Prescribing (see also Formulary Management, and Drug Benefit Design) | Utilization of pharmacy claims data to evaluate therapeutic interchange programs. 1999;5(4):331-34.  
- Actuarial analysis of private payer administrative claims data for women with endometriosis. 2007;13(3):262-72.  